Feraheme

Type: Product
Name: Feraheme
First reported Jul 11 2014 - Updated Jul 11 2014 - 1 reports

New Safety Recommendation for Ferumoxytol, EMA Says

To better manage the risk for serious hypersensitivity reactions, ferumoxytol should be given by infusion over the course of at least 15 minutes, instead of by injection, the European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee ... [Published Diabetes Care - Jul 11 2014]
First reported Jun 09 2014 - Updated Jun 09 2014 - 1 reports

AMAG Pharma gets patent term extension for ferumoxytol injection in US

AMAG Pharmaceuticals has announced that the US Patent and Trademark Office (USPTO) has issued a US patent term extension certificate extending the term of US Patent No. 6,599,498 by 1,209 days.With this extension the '498 patent will now expire 30 June ... [Published Pharmaceutical Business Review - Jun 09 2014]
First reported Apr 24 2014 - Updated Apr 24 2014 - 1 reports

AMAG Announces First Quarter 2014 Financial Results

17% Total Revenue Growth, Driven by Strong Feraheme PerformanceFavorable Terms Achieved in Recent $200 Million Convertible Debt OfferingEnding Cash Balance of $385 Million Provides Capital for Portfolio ExpansionConference call scheduled for 8:00 a.m. ... [Published GlobeNewswire - Apr 24 2014]
First reported Feb 10 2014 - Updated Feb 10 2014 - 1 reports

AMAG Pharmaceuticals Announces Proposed Offering of $150 Million of Convertible Senior Notes due 2019

WALTHAM, Mass., Feb. 10, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that it intends to offer, subject to market and other conditions, $150 million aggregate principal amount of Convertible Senior Notes due 2019 (the ... [Published GlobeNewswire - Feb 10 2014]
First reported Feb 03 2014 - Updated Feb 04 2014 - 2 reports

AMAG Pharma's ferumoxytol gets new US patent

AMAG Pharmaceuticals, Inc. has received a key new US patent for ferumoxytol, Patent No. 8,591,864, Polyol and Polyether Iron Oxide Complexes as Pharmacological and/or MRI Contrast Agents, expiring in March 2020 from Patent and Trademark Office (USPTO ... [Published PharmaBiz - Feb 04 2014]

Quotes

AMAG chief executive officer William Heiden said, "This patent extension for ferumoxytol further lengthens our intellectual property protection and enhances the long-term value of a product that generated 28 percent revenue growth in the U S in 2013 for our company."
"We are pleased to announce this new patent for ferumoxytol that is especially important for the long-term value of a product that generated 28 percent revenue growth last year in the United States" commented Frank Thomas, chief operating officer of AMAG

More Content

All (6) | News (6) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
New Safety Recommendation for Ferumoxytol, EMA ... [Published Diabetes Care - Jul 11 2014]
AMAG Pharma gets patent term extension for feru... [Published Pharmaceutical Business Review - Jun 09 2014]
AMAG Announces First Quarter 2014 Financial Res... [Published GlobeNewswire - Apr 24 2014]
AMAG Pharmaceuticals Announces Proposed Offerin... [Published GlobeNewswire - Feb 10 2014]
AMAG Pharma's ferumoxytol gets new US patent [Published PharmaBiz - Feb 04 2014]
AMAG Pharmaceuticals gets new US patent for fer... [Published Pharmaceutical Business Review - Feb 03 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.